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that the trend in use of insulin in the Czech republic
should be interpreted positively. Similarly, the decrease of
sulfonylurea use and the increase of that of metformin
are good news. New drugs may offer better treatment op-
tions, however, their actual value should be properly as-
sessed in clinical practice.
PDG20
A SIMULATION MODEL TO CALCULATE LONG-
TERM COSTS AND LIFE EXPECTANCY 
DEPENDENT ON POST PRANDIAL BLOOD 
GLUCOSE LEVELS IN DIABETES PATIENTS
Palmer AJ1, Roze S1, Nicklasson L2, Foos V1
1CORE Center for Outcomes Research, Basel, Switzerland; 
2Novo Nordisk A/S, Bagsvaerd, Denmark
OBJECTIVES: Recent population studies and meta-anal-
yses indicate that increased post-prandial blood glucose
(PPG) level is an independent risk factor for coronary
heart disease (CHD), stroke, cardiovascular disease (CVD)
death. A modeling study was performed to combine best
available data with costs of complications to project pos-
sible long-term clinical and cost outcomes for patients
with different baseline PPG levels.
METHODS: Risks of CHD, stroke, and CVD death de-
rived from Framingham formulae were combined with
PPG-dependent hazard ratios for incident CHD, stroke,
and CVD death to calculate life expectancy dependent on
baseline PPG. Direct costs of cardiovascular complica-
tions were projected over patients’ lifetime using a Markov
simulation model. Costs of treating cardiovascular com-
plications were retrieved from published sources. A French,
third-party-payer cost perspective was taken, and only di-
rect costs were included in the analysis. Costs were dis-
counted at an annual rate of 5%.
RESULTS: A typical population of type 2 diabetes pa-
tients aged 60.1 years with PPG levels of 15.3, 14.7, or
13.8 mmol/l at baseline was calculated to have life ex-
pectancies of 18.9, 19.4, and 19.9 years respectively.
Lifetime costs per patient (discounted at 5% per annum)
due to CVD complications were calculated to be FF
58,793, FF 57,912, and FF 56,565 respectively.
CONCLUSIONS: Patients with lower PPG levels are
likely to have improved life expectancy and reduced costs
due to cardiovascular complications. It is possible that
newer interventions that improve PPG levels will be cost-
effective, as the costs of interventions will be offset by re-
duced costs due to cardiovascular complications.
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OBJECTIVES: While the patient-reported effects of hy-
poglycemia have been investigated, little has been done
with hyperglycemia. This research was designed to en-
hance our understanding in this area.
METHODS: Using hand-held computers we assessed the
acute and cumulative effects of hyperglycemia on mood
and cognitive functioning. The sample consisted of 105
adults with type 1 diabetes mellitus who entered their de-
gree of symptoms (tired/sleepy, dry eyes/nose/mouth,
sweet taste, need to urinate), cognitive functioning (sub-
tractions, verbal fluency and choice-reaction time tests)
and their blood glucose (BG) over four weeks. In addi-
tion, they completed several psychometric instruments,
including the Diabetes Quality of Life scale.
RESULTS: All four symptoms steadily increased as BG
rose in the following increments: 110-144mg/dl; 145-180
mg/dl; 181-220 mg/dl; 220-270 mg/dl; 270mg/dl (p 
.001). Only verbal fluency and mental arithmetic perfor-
mance worsened with hyperglycemia (BGs  270, p 
.005). Individuals with more frequent BGs  160mg/dl
reported more worry about hyperglycemia, poorer qual-
ity of life and more hassles around symptoms and com-
plications, while being less likely to perform non-routine
tasks to avoid hyperglycemia.
CONCLUSIONS: Both between- and within-subject anal-
yses of acute and cumulative effects demonstrated hyper-
glycemia has psychological consequences in type 1 diabetes
mellitus and may result in less motivation to change rou-
tine behaviors to reduce the frequency of hyperglycemia.
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OBJECTIVE: To evaluate the validity and reliability of
the English version of KINDL (a self-administered ge-
neric quality of life instrument originally developed in
German) in Singaporean children with diabetes.
METHODS: Consecutive patients with diabetes (both
types I and II) attending the endocrinology clinic at Kan-
dang Kerbau Women and Children’s Hospital were asked
to fill in the KINDL questionnaire. Healthy controls were
recruited via street interview conducted outside commu-
nity libraries located in different parts of the island.
RESULTS: Thirty-five diabetics (mean age: 14.5  1.48
yrs, 17 males and 18 females) and 34 healthy controls
(mean age: 14.5  1.05 yrs, 17 males and 17 females)
completed the questionnaire. The overall result showed
that diabetic patients have a significantly higher overall
score compared to the controls (patient vs. control: 57.0 
8.7 vs. 48.8  8.8*, p  .01). Item reduction of individ-
ual domains did not change the overall pattern or the dif-
ference in magnitude between scores obtained by the two
groups. However, there were improvements (in the vicinity
of four to five percent) in overall scores when either the
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“Personal” or “School” domain was eliminated, indicat-
ing the questionnaire is sensitive to the cultural and social
differences between Asian and European cultures. The re-
liability of the instrument as measured by Cronbach’s
alpha for the six domains for the diabetics ranges from
0.31 to 0.75.
CONCLUSION: Although the results appear improba-
ble, they agree with the cultural and social characteristics
of Singapore where the educational system is highly
stressful. Parents of diabetic children may have lower ex-
pectations of their children due to their condition, and
hence the perceived better QOL among the diabetic chil-
dren. However, more data needs to be collected to con-
firm this observation. *Maximum possible score of 100.
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OBJECTIVE: To highlight the effects incurred in the
pharmaco-utilization and in the total expenses for dys-
peptic patients by the introduction of a disease-manage-
ment guideline.
METHODS: A retrospective reading of an administrative
billing database in the Ravenna Local Health Unit was
performed for all health-assisted subjects of 10 GPs who
had previously developed and agreed to a clinical guide-
line to manage dyspeptic patients (Dyspro GPs) as well as
by a group of 30 self-regulated GPs (Control GPs). The
latter group was selected ex post so as not to be signifi-
cantly different from the former in terms of personal and
patient characteristics. According to anti-dyspeptic treat-
ment, patients were grouped as having had or not pre-
scriptions between 01/01/1999 and 12/31/1999. Dyspep-
tic subjects were divided as having had or not an earlier
anti-dyspeptic treatment (new users/users). The follow-up
period lasted 365 days.
RESULTS: A total of 51,904 subjects were enrolled, of
which 23.1% were enrolled by the Dyspro GPs and
76.9% by the Control GPs. The percentage of dyspeptic
patients accounted for 17.6% and 15.0% respectively of
subjects enrolled by the Dyspro GPs and the Control
GPs. The average age of dyspeptic patients was 57.1 
18.6 years and 57.3  18.9 years (p  ns) and the per-
centage of males was 40.1 and 42.0 (p  ns), respectively
in the Dyspro GPs and Control GPs groups. The average
drug costs for new users (35.76 vs 38.56) and users
(107.51 vs 113.73) was higher as was the average
hospitalization cost for new users (65.78 vs 70.84)
and users (61.13 vs 87.40) in patients enrolled by the
Control GPs. Casualty department access and gas-
troscopies were not different among patients enrolled by
the physician groups.
DISCUSSION: Pharmaceutical and hospital expenditures
decreased as a consequence of the introduction of a dis-
ease-management guideline.
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OBJECTIVE: Rabeprazole (Pariet) is a new proton-pump
inhibitor, which offers fast and consistent acid control.
Randomized controlled studies showed that rabeprazole
in active peptic ulcer is comparable to omeprazole and
more effective than ranitidine. We performed economic
evaluations of rabeprazole, omeprazole and ranitidine in
active gastric and duodenal ulcers.
METHODS: A decision tree model (DATA 3.0 Treeage
Software Inc.) was applied for retrospective analysis of
peptic ulcer healing rate in controlled clinical trials of the
three drugs. Direct costs of standard treatment in a hospi-
tal setting (six and four weeks for gastric and duodenal
ulcers respectively) were calculated. They included hospi-
tal bills, investigations and drug-acquisition costs. Cost-
minimization and cost-effectiveness analyses were used to
evaluate rabeprazole vs. omeprazole and rabeprazole vs
ranitidine respectively. To calculate the incremental cost-
effectiveness ratio, we utilized the rate of improvement in
well-being after two weeks of treatment.
RESULTS: The direct costs of rabeprazole and ranitidine
in active duodenal ulcer were comparable ($261,21 vs
$263,28), but the proton pump inhibitor was signifi-
cantly more cost-effective than the H2-blocker (incre-
mental cost-effectiveness ratio 0,43 vs 4,66). The differ-
ence was due to the higher healing rate and faster effect
of rabeprazole. The direct costs of rabeprazole and ome-
prazole in active duodenal and gastric ulcer were
$248,21 vs $266,94 and $311,53 vs $332,77 respec-
tively. The difference was due to lower acquisition cost of
rabeprazole.
CONCLUSION: Rabeprazole may offer economic ad-
vantages over omeprazole and ranitidine in hospital
treatment of active gastric and duodenal ulcers.
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